Hybrid therapy with pilsicainide and pulmonary vein isolation for atrial fibrillation

Circulation Journal

Volumn 69, Issue 12, 2005, Pages 1503-1507

  Tojo, Hideaki ^a   Kumagai, Koichiro ^a   Noguchi, Hiroo ^a   Ogawa, Masahiro ^a   Yasuda, Tomoo ^a   Nakashima, Hideko ^a   Zhang, Bo ^a   Miura, Shin Ichiro ^a   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Antiarrhythmic agents; Atrium; Fibrillation; Pulmonary veins

Indexed keywords

PILSICAINIDE;

ADULT; ARTICLE; CATHETER ABLATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ELECTROPHYSIOLOGY; FEMALE; HEART ATRIUM FIBRILLATION; HEART CONDUCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PULMONARY VEIN; RECURRENT DISEASE; TREATMENT OUTCOME;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CATHETER ABLATION; ELECTROPHYSIOLOGY; FEMALE; HEART ATRIA; HEART BLOCK; HEART CONDUCTION SYSTEM; HUMANS; LIDOCAINE; MALE; MIDDLE AGED; PULMONARY VEINS; REFRACTORY PERIOD, ELECTROPHYSIOLOGICAL; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 28544439805     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.69.1503     Document Type: Article

References (20)

1. Suttorp MJ, Kingma JH, Lie AHL, Mast EG. Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am J Cardiol 1989; 63: 693 - 696.
2. Fresco C, Proclemer A, Pavan A, Buia G, Vicentini A, Pavan D, et al. Intravenous propafenone in paroxysmal atrial fibrillation: A randomized, placebo-controlled, double-blind, multicenter clinical trial (Paroxysmal Atrial Fibrillation Italian Trial (PAFIT)-2 Investigators). Clin Cardiol 1996; 19: 409 - 412.
3. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339: 659 - 666.
4. Chen SA, Hsieh MH, Tai CT, Tsai CF, Prakash VS, Yu WC, et al. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: Electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation 1999; 100: 1879 - 1886.
5. Haissaguerre M, Jais P, Shah DC, Garrigue S, Takahashi A, Lavergne T, et al. Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci. Circulation 2000; 101: 1409 - 1417.
6. Tada H, Naito S, Kurosaki K, Ueda M, Ito S, Shinbo G, et al. Segmental pulmonary vein isolation for paroxysmal atrial fibrillation improves quality of life and clinical outcomes. Circ J 2003; 67: 861 - 865.
7. Noguchi H, Kumagai K, Yasuda T, Ogawa M, Tojo H, Saku K. Conduction recovery after pulmonary vein isolation for atrial fibrillation. Circ J 2005; 69: 65 - 68.
8. Kirchhof C, Wijffels M, Brugada J, Planellas J, Allessie M. Mode of action of a new class IC drug (ORG 7797) against atrial fibrillation in conscious dogs. J Cardiovasc Pharmacol 1991; 17: 116 - 124.
9. Wang J, Bourne GW, Wang Z, Villemaire C, Talajic M, Nattel S. Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation: Importance of use-dependent effects on refractoriness. Circulation 1993; 88: 1030 - 1044.
10. Iwasa A, Okumura K, Tabuchi T, Tsuchiya T, Tsunoda R, Matsunaga T, et al. Effects of pilsicainide and propafenone on vagally induced atrial fibrillation: Role of suppressant effect in conductivity. Eur J Pharmacol 1998; 356: 31 - 40.
11. Kanki H, Mitamura H, Takatsuki S, Sueyoshi K, Shinagawa K, Sato T, et al. Postrepolarization refractoriness as a potential anti-atrial fibrillation mechanism of pilsicainide, a pure sodium channel blocker with slow recovery kinetics. Cardiovasc Drugs Ther 1998; 12: 475 - 482.
12. Sakai R, Inoue D, Ishibashi K, Inoue M, Shirayama T, Yamahara Y, et al. Kinetics of frequency-dependent conduction delay by class I antiarrhythmic drugs in human atrium. J Cardiovasc Pharmacol 1995; 25: 953 - 960.
13. Atarashi H, Inoue H, Hiejima K, Hayakawa H. Conversion of recent-onset Atrial Fibrillation by a single oral dose of Pilsicainide (Pilsicainide Suppression Trial on atrial fibrillation): The PSTAF Investigators. Am J Cardiol 1996; 78: 694 - 697.
14. Kumagai K, Abe H, Hiraki T, Nakashima H, Oginosawa Y, Ikeda H, et al. Single oral administration of pilsicainide versus infusion of disopyramide for termination of paroxysmal atrial fibrillation: A multicenter trial. Pacing Clin Electrophysiol 2000; 23: 1880 - 1882.
15. Chen YJ, Chen SA, Chang MS, Lin CI. Arrhythmogenic activity of cardiac muscle in pulmonary veins of the dog: Implication for the genesis of atrial fibrillation. Cardiovasc Res 2000; 48: 265 - 273.
16. Chou CC, Zhou S, Miyauchi Y, Pak HN, Okuyama Y, Fishbein MC, et al. Effects of procainamide on electrical activity in thoracic veins and atria in canine model of sustained atrial fibrillation. Am J Physiol Heart Circ Physiol 2004; 286: H1936 - H1945.
17. + channel blocker pilsicainide on the electrophysiologic properties of pulmonary veins in patients with atrial fibrillation. J Cardiovasc Electrophysiol 2004; 15: 1396 - 1401.
18. Nabar A, Rodriguez LM, Timmermans C, van den Dool A, Smeets JL, Wellens HJ. Effect of right atrial isthmus ablation on the occurrence of atrial fibrillation: Observations in four patient groups having type I atrial flutter with or without associated atrial fibrillation. Circulation 1999; 99: 1441 - 1445.
19. Paydak H, Kall JG, Burke MC, Rubenstein D, Kopp DE, Verdino RJ, et al. Atrial fibrillation after radiofrequency ablation of type I atrial flutter: Time to onset, determinants, and clinical course. Circulation 1998; 98: 315 - 322.
20. Huang DT, Monahan KM, Zimetbaum P, Papageorgiou P, Epstein LM, Josephson ME. Hybrid pharmacologic and ablative therapy: A novel and effective approach for the management of atrial fibrillation. J Cardiovasc Electrophysiol 1998; 9: 462 - 469.